METHODOLOGICAL RESEARCH RECORD

An SSMM-Informed Clinical Decision Architecture for Staged Laser Iris Depigmentation

Development, documentation logic and priorities for independent validation.

Mustafa Mete, MD · Ophthalmology · Lumineyes™ Research · 2026

Conceptual illustration of a human iris connected to four ophthalmic clinical assessment and decision domains.
METHODOLOGY · RESEARCH OWNER PAGE

This methodological paper examines how distinct clinical observations can be connected through a traceable decision architecture for staged laser iris depigmentation. The objective is not to restate the Lumineyes™ operating standard, but to define which records, comparisons and independent tests would show whether a structured approach adds decision value.

Manuscript status: Submitted to Preprints.org and undergoing editorial screening. No Preprints.org DOI has been assigned. The independently published 24-page Lumineyes™ Clinical Practice Standard is a separate research document.

The research question

Can explicit, eye-specific decisions based on eligibility, current ocular state, prior-stage response and independent authorization be documented reproducibly—and do those records improve prediction, consistency or clinical decision utility beyond baseline measurements and cumulative exposure alone?

A protocol can contain clinically sensible procedures yet remain difficult to audit if eligibility, monitoring findings and the decision to expose are merged into a single “approved” field. The proposed architecture separates these judgments so they can be evaluated rather than assumed.

The broader clinical journey and sequential patient assessment are described in the Laser Eye Color Change Procedure guide; this methodological paper focuses specifically on making the physician’s decisions traceable and testable.

Four gates, four distinct records

Four-gate methodological architecture: eligibility, completed eye safety checkpoint, prior-stage response and independent physician authorization.
Figure 1. Four-stage records are conceptually separate; an initial treatment has no previous stage to evaluate.

Gate A · Eligibility

Patient/eye screening, contraindication category and reasons for eligibility or deferral, with a decision date and an accountable reviewer.

Gate B · Safety checkpoint

A complete and time-specific assessment of pressure, anterior chamber, cornea and angle/outflow findings, including the integrated L-SAFE state.

Gate C · Prior-stage response

For repeat exposures, document intended change, response trajectory, unresolved events and the reason a new stage is being considered. For the first planned exposure this gate is marked not applicable, not missing.

Gate D · Independent authorization

A separate physician decision to proceed, defer, modify, close or request additional information. S0 readiness cannot automatically authorize an exposure.

Minimum audit-ready data model

A reproducible clinical record needs stable patient and eye identifiers, encounter and stage IDs, decision timestamps, eligibility category, measured safety domains, response findings, missing-data reasons, and stage disposition. Individual findings must remain accessible even when an integrated safety state is assigned.

RecordRequired distinctionPotential audit question
EligibilityPolicy category vs eye findingsCan another reviewer reproduce the stated candidacy decision?
CheckpointRaw measurements vs L-SAFE stateAre withheld/stop states consistently identified?
ResponsePigmentary vs tissue/functional observationsDoes previous-stage response add information beyond baseline?
AuthorizationReadiness vs actual permissionCan each exposure or closure be traced to a recorded decision?

Position within the SSMM research program

SSMM supplies an intended targeting and tissue-response framework; LIPS provides a proposed pigment phenotype vocabulary; L-OAT proposes broader optical and structural descriptors; L-SAFE organizes current anterior-segment safety findings; and LRS concerns distinguishability of longitudinal responses. Their roles are complementary but none independently establishes the benefit of the four-gate decision architecture.

For the procedure-level anatomical and biological context in which these assessments arise, see the Laser Iris Depigmentation guide. The Lumineyes™ Clinical Practice Standard separately describes the full practice and documentation policy.

L-SAFE safety staging integrates intraocular pressure, anterior chamber, cornea and angle outflow findings into S0 through S3 states.
Figure 2. S0 readiness is not automatic treatment permission; S1 and S2 withhold exposure, and S3 closes the stage sequence.

Phenotype notation should not be treated as an efficacy prediction or laser-dose algorithm. Similarly, the L-SAFE states describe an interpretive checkpoint without replacing direct measurement or judgment.

What would count as meaningful validation?

The proposed evaluation moves in three directions: first document completeness, reliability and missingness; then assess incremental prediction and decision utility against simpler models; finally test transportability, policy sensitivity and independent replication in settings outside the development program.

Independent validation roadmap assessing data completeness, agreement, longitudinal value and external replication of the clinical decision framework.
Figure 3. Proposed evaluation design, not results from an implemented validation study.

Important negative findings are informative. If a four-gate record is too incomplete to be reproduced, if prior-stage measurements add no held-out predictive value, or if external clinicians cannot implement the categories consistently, the corresponding contribution is weakened. Proposed rules should be revised or discarded rather than treated as validated by their existence.

Separation from mechanistic SSMM–IOP investigations

A change in measured intraocular pressure does not identify an underlying outflow mechanism. The published SSMM–IOP preprint and the separate L-TIDE computational research program address mechanistic questions and observability. Their model-based findings are not interchangeable with clinical outcome data or evidence that the decision architecture has been independently validated.

Manuscript and source standard

The manuscript presented for Preprints.org consideration is a separate methodological work. The author-controlled Lumineyes™ LID Clinical Practice Standard provides the more complete public practice and documentation specification.

An SSMM-Informed Clinical Decision Architecture · illustrated manuscript

Open or download the manuscript

Preprints.org: DOI to be added only after the manuscript has been posted and the record verified. Reference standard: Lumineyes™ LID Clinical Practice Standard v1.1 · Zenodo DOI: 10.5281/zenodo.24280545.

This owner page is a scientific overview of an author-controlled methodological draft. It is not an external validation report or a published clinical outcome study.

Research record prepared by Mustafa Mete, MD · Lumineyes™. The explanatory owner page and the linked documents remain distinct research records.
Conceptual illustration of a human iris linked to four clinical assessment and decision domains in the SSMM-informed Lumineyes framework.
Lumineyes Lumineyes Assistant ×
Structured clinical guidance • No automated free-text answers
Start Here
Ask a question or choose a topic above.
Explore how Lumineyes works, treatment sessions, results, safety, eligibility, cost, and appointments.